The Netherlands
Laigo Bio, founded in 2022 and based in The Netherlands, is a pioneering entity in the Biotechnology sector. Leveraging its proprietary SureTAC platform, the company focuses on the rapid development of dual-targeted therapies designed to eliminate membrane proteins responsible for driving diseases. This technology is built around straightforward bispecific antibody methodology, positioning Laigo Bio at the forefront of innovation in tackling challenging targets, some of which are currently dubbed as "undruggable."
The recent €5.50M seed investment on 01 March 2026, funded by Kurma Partners and Capital Partners, underscores significant investor confidence in Laigo Bio's potential to revolutionize the landscape of disease treatment. The company’s commitment to exploring new partnerships and innovate further in fields like oncology, neurobiology, and immunology signifies its proactive approach to creating life-changing therapeutic solutions.
